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Abstract
Objectives
Definitive sample sizes for clinical trials in rare diseases are usually infeasible. Bayesian
methodology can be used to maximise what is learnt from clinical trials in these circum-
stances. We elicited expert prior opinion for a future Bayesian randomised controlled trial
for a rare inflammatory paediatric disease, polyarteritis nodosa (MYPAN, Mycophenolate
mofetil for polyarteritis nodosa).
Methods
A Bayesian prior elicitation meeting was convened. Opinion was sought on the probability
that a patient in the MYPAN trial treated with cyclophosphamide would achieve disease
remission within 6-months, and on the relative efficacies of mycophenolate mofetil and
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cyclophosphamide. Expert opinion was combined with previously unseen data from a re-
cently completed randomised controlled trial in ANCA associated vasculitis.
Results
A pan-European group of fifteen experts participated in the elicitation meeting. Consensus
expert prior opinion was that the most likely rates of disease remission within 6 months on
cyclophosphamide or mycophenolate mofetil were 74% and 71%, respectively. This prior
opinion will now be taken forward and will be modified to formulate a Bayesian posterior
opinion once the MYPAN trial data from 40 patients randomised 1:1 to either CYC or MMF
become available.
Conclusions
We suggest that the methodological template we propose could be applied to trial design
for other rare diseases.
Introduction
Recently, the European Commission and subsequently the UK Department of Health priori-
tised strategies to improve the care of patients with rare diseases (prevalence 5 per 10,000)
[1]. Such strategies should consider alternative therapeutic trial designs for small anticipated
sample sizes [2]. The Bayesian approach begins by formally characterising prior opinion which
is then updated with collected data using Bayes theorem to obtain a posterior opinion to in-
form clinical practice. It can be particularly useful when the sample sizes required by traditional
frequentist designs are infeasible [2, 3]. But what is a Bayesian prior? And how do you elicit
one? Accounts have been given of Bayesian prior elicitation in the context of designing rando-
mised controlled trials [4–5] (RCTs). The findings of a Bayesian prior elicitation exercise have
been cited to motivate conduct of an RCT evaluating warfarin for the treatment of rheumatic
diseases [6]. However, such methods have yet to become part of routine practice for paediatric
trials. This paper describes the novel approach that was taken to elicit expert prior opinion to
inform the design of an RCT for a rare disease affecting children, polyarteritis nodosa (PAN).
A full account of the statistical aspects of the proposed approach is given elsewhere [7]. The
aim of the current paper is to provide further practical details on the steps taken to plan and
carry out the Bayesian prior elicitation meeting so this process can be replicated by clinical tri-
alists in other rare disease studies.
Polyarteritis nodosa and the MYPAN trial
Childhood PAN is a rare and severe multi-systemic vasculitic disease that affects approximate-
ly 1 per million children [8]; a full clinical description is provided elsewhere [8, 9]. Untreated,
mortality is close to 100% [10]; with aggressive immunosuppression mortality is 4% [9]. A
comprehensive literature search of published and unpublished studies relating to the treatment
of PAN was undertaken (full details of the search strategy and databases searched are available
upon request); an important finding was that there are no published or currently recruiting
RCTs relating to PAN in children. All of the paediatric reports identified were uncontrolled
study designs i.e. cohort and single-case studies, that rate as low-level evidence. Conclusions
based on RCTs in adults with PAN [11–14] with important implications for children are: a)
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treatment of severe PAN requires corticosteroids combined with intravenous cyclophospha-
mide (CYC); b) despite therapy, mortality associated with PAN in adults remains high at
4–22%; treatment-related toxicity contributes to this; c) adverse events (disease and treatment-
related) affect 54–100% patients; and d) avoidance of CYC in children is desirable if alterna-
tives exist since complications associated with CYC include infertility and malignancy.
The MYPAN study (Mycophenolate mofetil for childhood PAN) is an open-label non-infe-
riority RCT of mycophenolate mofetil (MMF) versus CYC for the treatment of PAN in chil-
dren (4–18 years), currently being set up. Table 1 compares the design of the MYPAN trial
with that of the MYCYC trial, an RCT comparing MMF with CYC for remission induction in
ANCA-associated vasculitis. The primary endpoint of the MYPAN study is disease remission
within six months of randomisation using a standard definition [15]. Due to its lower risk of
infertility/malignancy, MMF would be favoured [16] unless the 6-month remission rate on
MMF was more than 10% (absolute difference) smaller than that on CYC. A definitive frequen-
tist trial would require 513 patients per arm to have 90% power to declare MMF non-inferior
to CYC at the 2.5% one-sided significance level when remission rates on both treatments equal
70%. Previous experience suggests it would take well over 30 years to reach this sample size
[9,17], thus explaining why a paediatric trial for PAN has never been performed. Early plan-
ning of the MYPAN trial estimated that recruitment of 40 children across 30–40 European cen-
tres would be achievable over four years.
Instead, the MYPAN trial adopts a Bayesian approach, first characterising expert prior
opinion about the 6-month remission rate on CYC and the relative benefit of MMF as proba-
bility distributions before the trial begins, and then updating these distributions using Bayes
theorem once data become available [2]. This paper gives an account of how expert prior opin-
ion was elicited.
Table 1. Comparison of the design of 2 randomised controlled trials for vasculitis: MYPAN versus
MYCYC.
Trial name and
study population
MYPANa: PANb in children (4
and  18 years)
MYCYCc: ANCAd associated vasculitis
in adults & children (8 children, 132
adults)
Hypothesis MMFe is not inferior (<10% absolute
difference) to intravenous CYCf for
induction of remission
MMF is not inferior (<12% absolute
difference) to intravenous CYC for
induction of remission
Entry criteria i) Must fulfil classification criteria for
PAN; ii) 1or more major PVASg items
and/or 3 or more minor PVAS items; iii)
Must be newly diagnosed patients
i) Chronic inflammatory disease lasting at
least 4 weeks; characteristic histology on
biopsy and/or a positive ANCA; ii) 1 or
more major BVASh items and/or 3 or
more minor PVAS items; iii) Must be
newly diagnosed patients
Primary endpoint Remission within 6 months defined as
PVAS 0/63 on 2 consecutive readings at
least one month apart on protocol steroid
taper
Remission within 6 months defined as
BVAS 0/63 on 2 consecutive readings at
least one month apart on protocol steroid
taper
aMYPAN: Mycophenolate mofetil for childhood polyarteritis nodosa;
bPAN: polyarteritis nodosa;
cMYCYC: Mycophenolate mofetil versus cyclophosphamide for ANCA associated vasculitis;
dANCA: anti neutrophil cytoplasmic antibodies;
eMMF: Mycophenolate mofetil;
fCYC: cyclophosphamide;
gPVAS: Paediatric Vasculitis Activity Score;
hBVAS: Birmingham Vasculitis Activity Score.
doi:10.1371/journal.pone.0120981.t001
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Materials and Methods
Identifying and inviting clinical experts
A Prior Elicitation Meeting was convened. Paediatric consultants in rheumatology, nephrolo-
gy, immunology or other allied specialties were sought from across the UK and internationally,
with an interest in vasculitis and experience of looking after children with PAN (having seen
on average at least one case every two years). Invitations were sent to society email lists for the
Pediatric Rheumatology International Trials Organisation [18] (www.printo.it), the British So-
ciety for Paediatric and Adolescent Rheumatology (www.bspar.org.uk), the British Association
for Paediatric Nephrology (www.renal.org/BAPN), and the European Society for Pediatric Ne-
phrology (http://espn.cardiff.ac.uk/), and also to 81 paediatric clinics treating PAN identified
via Orphanet (www.orpha.net). Initial expressions of interest were received from 25 eligible re-
spondents, of whom (for logistical reasons) 15 were eventually able to attend the meeting. The
Expert Group comprised the following co-authors of this manuscript: MWB, CB, AC, RC, JD,
PD, DE, MF, MJ, SM, NM, A-MM, JP, A van R-K and OS. Participating experts were drawn
from across the EU and Turkey (see author affiliations).
No patients were involved in the Bayesian prior elicitation meeting. Instead, all participants
were expert investigators who had volunteered to participate in the meeting (and are co-au-
thors of this manuscript). Since participants were true investigators, rather than subjects in-
volved in research, we did not require ethics approval for the elicitation exercise. We therefore
followed the same process as other expert consensus exercises and did not seek written
consent.
Selection of the specific quantities to be elicited
Expert opinion was sought on the probability that a patient satisfying the entry criteria of the
MYPAN trial would succeed according to its primary endpoint. The probability of success for a
patient treated with CYC was denoted by pC, and expert views on the value of pC were elicited di-
rectly. The corresponding probability of successful treatment with MMF was denoted by pM, the
value of which was derived indirectly from expert clinicians using questions about the relative
merits of the two drugs. In statistical terms, this relative efficacy was expressed as the log-odds
ratio defined by θ = loge{pM/(1—pM)}—loge{pC/(1—pC)}. We interpret θ as a treatment effect,
that is, a measure of the advantage of MMF over CYC for improving the chance of disease remis-
sion within 6-months. Positive values of θ indicate that the chances of remission are higher on
MMF than CYC (superiority); values of θ close to 0 indicate equivalence of efficacy. The non-in-
feriority margin of δ = 0.1, meaning that MMF would be preferred if pM—pC –0.1, was fixed
in advance of the meeting by the clinical trial management group since this difference was felt to
be clinically important, and was similar to the definition of non-inferiority used in a previous
vasculitis trial (see below and Table 1).
Mathematical modelling of beliefs and uncertainties
Opinion on the value of pC was uniquely defined by two parameters designed to elicit the ex-
perts’ choice for the most likely value of pC, and their level of uncertainty about this value.
These values were sought by asking the experts two questions (Q1 and Q2 in S1 Table). Opin-
ion on the relative efficacy of CYC and MMF (θ) was modelled as a normal distribution, the pa-
rameters of which were determined by asking experts two questions (Q3 and Q4 in S1 Table).
From the resulting opinions about pC and θ, treated as independent, a consistent opinion
about pM was derived. The nature and strength of stated beliefs were characterised through the
mean and mode of the distributions of pC and pM. To illustrate this, Fig 1 summarises the prior
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Fig 1. Range of prior opinions elicited before introduction of the MYCYC data. Fig 1A) Comparison of Expert A’s prior densities for pC and pM. Expert A
thought the most likely value of pC is 0.65 and was 75% confident that pC exceeds 0.45. Expert A was optimistic about the relative efficacy of MMF stating that
the chance that MMF is superior to CYC is 63% while the chance it is inferior to CYC is 5%. Fig 1B) Comparison of Expert B’s prior densities for pC and pM.
Expert B thought the most likely value of pC is 0.8 and was 75% confident that pC exceeds 0.55. Expert B was more sceptical about the benefits of MMF,
stating that the chance that MMF is superior to CYC is 10%while the chance it is inferior to CYC is 50%. Given each expert’s prior opinion about pC and the
relative efficacies of MMF and CYC, a consistent prior for pM is derived.
doi:10.1371/journal.pone.0120981.g001
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distributions for two experts with extreme opinions about pC and pM relative to the rest of the
group. Experts were asked two further questions to verify that the elicited opinion reflected
their personal beliefs. Especially useful to the clinicians when considering their prior belief was
the calculation of the effective sample size [19] (ESS) of a prior distribution; in other words, pro-
viding clinicians with the numbers of patients in a hypothetical clinical trial that would be re-
quired to statistically generate that level of certainty they had expressed for the parameters. For
further details about these calculations, see [7]. The elicitation process was iterative, and the
mathematical models and bespoke computer software allowed for quick and clear graphical
representations of their densities. The consequences of adding hypothetical data sets to form
posterior distributions were also shown. The computer program [7] was written in R [20]
using the Shiny package [21] to create a user-friendly, interactive, interface. Software was tested
on statistics students (seeking opinions on quantities that they understood) and clinical experts
(PB, DE), which led to improvements and modifications.
Training of the expert participants
Fig 2 illustrates the sequence of activities undertaken during the two day meeting and the time
allocated to each. Four statistical facilitators were available throughout the two days to support
the elicitation process. The meeting began with an overview of PAN [9] and the evidence sup-
porting treatment options including the findings of RCTs in adults [11–14] (S2 Table). A talk
by one of the statistical facilitators (JW) introduced Bayesian reasoning, credibility intervals
and representation of treatment differences as log-odds ratios. A practice session was then
held. A glass jar containing 60 small wooden blocks, coloured either pink or black, was briefly
shown to the experts who were then asked for their opinions about the proportion of pink
blocks in the jar. Specifically, they were asked for the most likely proportion of pink blocks (in-
terpreted as the most likely value of their prior distribution) and for a value, pL, between 0 and
1, which they believed the true proportion of pink blocks exceeded with probability 0.75. Using
software similar to that to be used for the real elicitation, opinions were represented through
graphics, summaries and ESSs. Having chosen a prior, the wooden blocks were transferred to a
black bag, and four volunteers in turn each drew a sample of five, announced the number of
pinks, and replaced them. The emerging posterior distribution was displayed. This exercise al-
lowed the principles of the elicitation process and of the Bayesian method to be rehearsed in a
neutral setting. The purpose of the statistical training was to standardise the experts’ under-
standing of Bayesian methods so that they could interpret and check the goodness-of-fit of the
prior distributions determined during the formal elicitation process.
Elicitation of opinions
Each expert was given a structured questionnaire designed to systematically ascertain prior
opinion regarding outcomes for treatment with CYC and MMF (S1 File). Experts completed
their questionnaires independently, and then met individually with statistical facilitators to dis-
cuss their answers. The R program was used to display the consequences of the answers provid-
ed. Changes to answers were allowed following discussion with facilitators, until the expert was
happy that the model truly reflected their opinion.
Consensus prior distributions for θ and pC were then sought, allowing the group to decide
how to weight competing opinions. This was preferred to an automatic mathematical aggrega-
tion of individual prior distributions that would require the relevant competencies of partici-
pating experts to be quantified, or to working with multiple priors that would lead to multiple
posterior distributions and no clear trial conclusion. A nominal group technique process of
reaching consensus began with each expert individually commenting to the group on their
Elicitation of Expert Prior Opinion: Application to the MYPAN Trial
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Fig 2. Flow diagram illustrating the sequence of activities undertaken during the MYPAN prior elicitation meeting and the time allocated to each
activity.
doi:10.1371/journal.pone.0120981.g002
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answers to the structured questionnaire, starting with those with extreme values. Technical
misunderstandings were identified and corrected. Lengthy and constructive discussions took
place, with the ESS for the opinion about θ being particularly influential in leading to a reduc-
tion in the certainty expressed for this parameter. Potential results for the 40 patients in the
MYPAN study were considered, and the corresponding posterior distributions displayed to
show the relative influence of the prior and the data. Overnight reflection was allowed, and a
final consensus (agreed by the majority as reflecting their opinion) was reached on the morning
of the second day of the meeting.
Presentation of related trial results: the MYCYC trial
Once prior distributions had been determined for the parameters of interest, further informa-
tion was presented to the experts. This concerned the soon-to-be published MYCYC trial
(http://www.clinicaltrials.gov/show/NCT00414128) involving 132 adults and 8 children. The
design, treatment arms, and primary endpoint for MYCYC were similar to that planned for
MYPAN (Table 1), but the final results were not yet published.
Influence of MYCYC trial results on the prior opinion
Following the presentation of the MYCYC trial design, but before mention of any results, the
experts were asked their opinions of the relevance of the MYCYC results to those of MYPAN.
Individually they were tasked with completing another structured questionnaire (S2 File) de-
signed to elicit opinion about the relationship between probabilities of response for MYPAN
and MYCYC patients on CYC or MMF. Individuals’ answers were displayed on flip charts.
Consensus was reached after each expert had explained their views. After consensus had been
reached on the relationship between the results of the two trials, key results fromMYCYC were
presented and key points of comparison between the MYCYC and MYPAN trials were further
highlighted. Prior distributions from the first day were then updated by including the influence
of the MYCYC results; a full account of the statistical approach used to incorporate these his-
torical data into the prior distributions is provided in [7]. Revisions to opinions about the rela-
tionship between the two trials were invited. A final consensus about beliefs in the response
probabilities in the MYPAN population was then reached. Opinion about the allocation ratio
that should be used in the MYPAN trial was sought but views about the total sample size were
not since this number was considered fixed by the maximum feasible number of patients that
could be recruited within the timeframe of the trial.
Results
Experts’ final responses to the first structured questionnaire are available online (S1 Table).
Group discussion led some experts to change their initial answers, either because they had mis-
interpreted the questions, or because they accepted suggestions made by their colleagues. Based
on the consensus answers of the experts (Fig 3), the most likely value of the remission rate for
CYC was 0.70 (90% probability that pC lies between 30% and 91%); this opinion equated to an
ESS of 5 patients on CYC. The most likely remission rate on MMF was 0.65 (with 90% proba-
bility that pM lies between 21% and 90%). The strength of prior opinion concerning θ corre-
sponded to an ESS of 39 patients on each treatment.
The results of the MYCYC trial, in which 70 ANCA associated vasculitis patients were treat-
ed with CYC and 70 with MMF, were that 74% of patients on CYC achieved remission within
6 months, compared with 73% of patients on MMF. Incorporating the consensus relevance of
these data (S3 Table) resulted in the modified opinions summarised in Fig 4. The most likely
remission rates on CYC and MMF changed to 0.74 and 0.71 respectively. In terms of ESS, prior
Elicitation of Expert Prior Opinion: Application to the MYPAN Trial
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Fig 3. Expert prior opinion before introduction of the MYCYC data regarding 6-month remission rates using treatment with CYC or MMF for
children with PAN. Reprinted from [7] under a CC BY license, with permission from the authors, original copyright 2014. Prior opinion was that the
most likely value for pC was 0.7; 90% and 50% credibility intervals were (0.30, 0.91) and (0.50, 0.78), respectively. The effective sample size was 5 patients
on CYC. The prior for pM is derived from those for pC and θ. It had mode = 0.65; 90% and 50% credibility intervals were (0.21, 0.90) and (0.41,
0.74), respectively.
doi:10.1371/journal.pone.0120981.g003
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Fig 4. Influence of the MYCYC trial results on expert prior opinion regarding 6-month remission rates using treatment with CYC or MMF for
children with PAN. Reprinted from [7] under a CC BY license, with permission from the authors, original copyright 2014. Fig 4A): Influence of
MYCYC results on prior opinion for pC. The modified prior distribution for pC after considering the MYCYC results had mode = 0.74; 90% and 50% credibility
intervals were (0.51, 0.86) and (0.63, 0.78), respectively. This level of certainty is equivalent to what would be obtained from a clinical trial involving 17
patients treated with CYC (effective sample size). Fig 4B): Influence of MYCYC results on prior opinion for pM. The modified prior for pM after considering the
MYCYC results had mode = 0.71; 90% and 50% credibility intervals were (0.45, 0.85) and (0.59, 0.76), respectively. Fig 4C): Comparison of the final expert
prior opinions for pC and pM incorporating the MYCYC data.
doi:10.1371/journal.pone.0120981.g004
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information on pC was now worth 17 patients on CYC and that on θ worth 48 patients on each
treatment. The effect of 70 real patients per treatment arm in MYCYC was to increase the for-
mer ESS by 12 and the latter by 9, showing how the new information fromMYCYC was down-
weighted in the context of MYPAN. The MYCYC data had a substantial influence on opinions
of the absolute values of remission rates on the two treatments, but much less influence on
their relative merits (data not shown). Fig 5 shows how these final prior opinions would change
after two hypothetical outcomes of MYPAN itself.
Discussion
Amajor challenge in rare diseases is conducting clinical trials with sufficient power to inform
best clinical practice when anticipated sample sizes are small. Historically, this has been a
major barrier in rare paediatric autoimmune diseases and almost certainly explains why a clini-
cal trial for PAN in children has never been undertaken. We have adopted a Bayesian clinical
trial design to overcome this barrier, and describe the process for elicitation of expert prior
opinion to inform the design of the MYPAN trial, the first RCT for childhood PAN.
Recently, guiding principles in relation to good practice for prior opinion elicitation have
been suggested [22], and where possible we have adopted these. Using a formal Bayesian prior
elicitation exercise we have established that the most likely rates of disease remission within 6
months on CYC and MMF are 74% and 71%, respectively. These findings are likely to remain
the state of knowledge until they can be updated with data received fromMYPAN. Posterior
distributions will quantify the uncertainty about disease remission rates that remains once the
MYPAN data are available. This uncertainty means that conclusions about whether MMF is
non-inferior to CYC are unlikely to be definitive. However, it would take a prospective rando-
mised trial recruiting over 500 patients per arm to achieve that. That said, for a rare disease like
PAN, clinically informative results can still be obtained.
Our results revealed that experts can be quite uncertain of absolute effects of treatments, but
more convinced of their relative merits. In other words, for MYPAN, experts were uncertain
about the precise value of pC but more confident that pM would not be too dissimilar. If the ac-
tual data fromMYPAN confirm the prior, then confidence in those opinions will grow and this
in turn would have an appreciable impact on the treatment approaches that would subsequent-
ly be adopted. If the data are at odds with the prior, this will be reflected in a clear and docu-
mented change in opinion: the prior is not so strong that contradictory evidence is dismissed.
In the prior elicitation meeting, experts accepted the Bayesian paradigm as a framework for
representing their prior knowledge and uncertainty. We canvassed opinion from a pan-Euro-
pean group of experts. However, as the experts were volunteers, their views may not be repre-
sentative of those who did not accept the invitation to participate.
In conclusion, the methodology developed for this exercise allows formal and structured
learning about the treatment of childhood PAN to begin, and to be updated by MYPAN and
studies beyond that. We suggest that this methodological template could be applied to trial de-
sign for other rare diseases, and is of particular relevance to rare autoimmune conditions that
currently lack a good evidence base for treatment.
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Fig 5. Posterior densities for pC and pM based on the prior of Fig 4 following observation of 20 patients treated on each study arm, with 14/20
successes on CYC and 14/20 successes on MMF (Hypothetical Scenario 1), or with 14/20 successes on CYC and 7/20 successes on MMF
(Hypothetical Scenario 2). Fig 5A) and 5C) are reprinted from [7] under a CC BY license, with permission from the authors, original copyright 2014.
Fig 5A): Prior and posterior densities for pC in Hypothetical Scenario 1. Fig 5B): Prior and posterior densities for pM in Hypothetical Scenario 1. Fig 5C): Prior
and posterior densities for pC in Hypothetical Scenario 2. Fig 5D): Prior and posterior densities for pM in Hypothetical Scenario 2.
doi:10.1371/journal.pone.0120981.g005
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